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ABSTRACT 
Objective: To identify frequency, type, severity and predictors of potential drug-drug interactions(pDDIs), potential drug-food interactions(pDFIs), 
potential drug-alcohol interactions(pDAIs) and potential drug-tobacco interactions(pDTIs) and most frequently interacting drug combination pairs 
in hospitalized patients from departments(depts) of General Medicine(GM), Orthopedic(Ortho), Gynecology(OBG), Pulmonology(Pulmo), General 
Surgery (GS), Psychiatry (Psych), Otolaryngology(ENT) and Dermatology (Derm) of study population. 
Methods: A Prospective Observational Study was conducted in eight major dept's of a tertiary care teaching hospital for a period of 6 mo. A sample 
size of 650 prescriptions reflecting admission no's for each department were used. 
Results: A total of 650 patients were included in the study. Among them, 282(43.4%) were males and 368(56.6%) were females. The mean age of 
the study population was 39.67±15.23. A total of 487 pDDIs, 734 pDFIs, 586 pDAIs and 159 pDTIs were found out of 650 hospitalized episodes. OBG 
showed the highest pDDIs and pDAIs. Highest pDFIs and pDTIs were seen in Pulmo. The majority of DDIs were minor, DFIs and DAIs were moderate 
and DTIs were of major in severity. Pharmacokinetic types of interactions were seen in the majority of the depts. Logistic regression analysis 
showed that Polypharmacy was associated with the occurrence of DIs. Most of the DIs repeated several times in particular depts and a list of these 
combinations was prepared. 
Conclusion: With the high occurrence of overall DIs and characteristic patterns of DIs combination pairs among different departments of the 
hospital, the presence of clinical pharmacists in hospitals can play a great role, especially in developing nations like India where their role in 
hospitalized settings is always controversial.  
Keywords: Drug interactions, Drug-drug interactions, Drug-food interactions, Drug-alcohol interactions, Drug-tobacco interactions, Departments, 
Drug combination pairs, Clinical Pharmacist 
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INTRODUCTION 
Drug interactions(DIs) are one of the most common causes of 
adverse drug reactions and continues to be a public health challenge 
in both developed and developing countries in the world. These DIs 
can be defined as an alteration in the efficacy or toxicity of a drug 
caused by concomitant administration with other drugs, food, 
beverages, and other supplements [1]. With thousands of drugs 
available worldwide and a substantial increase in drug discovery 
processes, the range of possibilities for drug interactions is 
considerable. It is reported that elderly patients with their increased 
complexity of the disease and therapeutic regimen are more 
susceptible to the occurrence of DIs [2].  
However, these DIs may also occur independently in patients of all 
age groups. As the pattern of medications received by patients of 
different age groups and in different departments in a hospital is 
more complex, it is not easy to estimate the occurrence of DIs 
accurately. The prescriptions having 3 or more drugs had increased 
from 11.8% in 1988-1994 to 20.08% in 2007-2010 and having 5 or 
more drugs have increased from 4% to 15.01% during the same 
time period in the United States [3, 4]. 
The mechanism implicated in the occurrences of DIs can be 
Pharmacokinetic (PK) with alteration in the absorption, distribution, 
metabolism, and excretion of object drug or Pharmacodynamic (PD) in 
which interaction is close to the target organ and has an additive or 
antagonistic effect on the pharmacological action of the object drug [5].  
About 30% of all adverse drug events increasing the hospital stay 
and healthcare cost of patients are related to DIs [6, 7]. 
Therefore, reviewing the therapy by the clinical pharmacist based on 
the physiological conditions of the patient and considering the type 
of allergies, medication history, and social habits of the patient, the 
clinical pharmacist may play a key role in preventing different types 
of DIs and adverse events. 
Not much data is available on the distribution pattern of DIs in 
different department's (dept's) of the hospital. There are several 
published data regarding the pattern of DIs in a particular department 
of the hospital or the overall interactions found in particular age 
groups [2, 8]. Further, the literature has mainly focused on drug-drug 
interactions (DDIs), while there are also risks of occurrence of DIs with 
food, alcohol, and tobacco [9-11]. There are some very well-known 
potential drug-food interactions that are potentially dangerous and 
may result in therapeutic failure. With an increasing population taking 
alcohol and tobacco, many drugs interact adversely with them. Hence 
this study aims to find out the frequency, type, severity, and predictors 
of potential drug-drug interactions (pDDIs), potential drug-food 
interactions (pDFIs), potential drug-alcohol interactions (pDAIs) and 
potential drug-tobacco interactions (pDTIs) and the most frequently 
interacting drug combination pairs in hospitalized patients from 
departments (depts) of General medicine (GM), Orthopedic (Ortho), 
Pulmonology (Pulmo), General Surgery (GS), Psychiatry (Psych), 
Otolaryngology (ENT) and Dermatology (Derm) of the study 
population, which will help the doctor to be aware of these 
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interactions when prescribing and a pharmacist working in clinical 
settings to gain a well-grounded knowledge in the prevention, 
detection, and management of these interactions and contribute 
greatly to the patient's safety and wellbeing. 
 
Table 1: Demographic profile of the patients from different departments of the hospital 
S. No. Parameters Total no % 
 1 Gender wise distribution 
 General Medicine   
 -Male 55 55% 
 -Female 45 45% 
 Orthopedic   
 -Male 45 45% 
 -Female 55 55% 
 Gynecology   
 -Male 0 0% 
 -Female 100 100% 
 Surgery   
 -Male  50 50% 
 -Female 50 50% 
 Otolaryngology   
 -Male 39 39% 
 -Female 61 61% 
 Pulmonology   
 -Male 35 70% 
 -Female 15 30% 
 Psychiatry   
 -Male 33 66% 
 -Female 17 34% 
 Dermatology   
 -Male 25 50% 
 -Female 25 50% 
2 Age wise distribution 
 General Medicine   
 18-30years 28 28% 
 31-60years 60 60% 
 >60years 12 12% 
 Orthopedic   
 18-30years 24 24% 
 31-60years 71 71% 
 >60years 5 5% 
 Gynecology   
 18-30years 58 58% 
 31-60years 42 42% 
 >60years 0 0% 
 Surgery   
 18-30years 21 21% 
 31-60years 68 68% 
 >60years 11 11% 
 Otolaryngology   
 18-30years 30 30% 
 31-60years 60 60% 
 >60years 10 10% 
 Pulmonology   
 18-30years 10 20% 
 31-60years 28 56% 
 >60years 12 24% 
 Psychiatry   
 18-30years 12 24% 
 31-60years 33 66% 
 >60years 5 10% 
 Dermatology   
  18-30years 29 58% 
 31-60years 19 38% 
 >60years 2 4% 
 
 
MATERIALS AND METHODS 
Methodology 
The research was conducted in a tertiary teaching hospital, Bhaskar 
General Hospital, for a period of 6 mo (i.e. June 2019-November 
2019) in GM, OBG, Ortho, GS, Pulmo, ENT, Psych, and Derm depts. 
Type of study 
Prospective Observational Study. 
Study design 
The data was collected from the patient's medical record or 
medical profile sheet for a duration of 6 mo from 8 different 
departments in a tertiary care hospital. The data collected from 
the patient's medical record included demographic details of 
patient, chief complaint, history of present illness, lab 
investigations, past medical conditions, medical or any potential 
allergic history, final diagnosis, day-wise medication therapy with 
their dose, frequency, route, duration of therapy and dosage-form. 
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Consent was obtained from all subjects before the study. All data 
were collected and analyzed for this study.  
Inclusion criteria were patients of both gender aged more than 18 y 
with complete clear data and exclusion criteria were patients with 
less than 18 y old and prescription with uncleared data. 
A total of 650 prescriptions with 100 prescriptions each were from 
GM, Ortho, OBG, GS, and ENT, and 50 each from Psych, Pulmo, and 
Derm depts reflecting admission numbers for each dept were 
assessed for pDIs. 
As the minimum sample size recommended by the W. H. O. is 600, 
the current sample size was considered as an appropriate sample 
size for this study. 
Study measures 
pDDIs, pDFIs, pDAIs, and pDTIs were detected using the drug 
interaction checking software tool Micromedex®–2.7 and 
www.drugs.com database. 
Statistical analysis 
For categorical variables, frequency/percentages were calculated, and 
continuous variables were expressed as mean±SD. The binary logistic 
regression model was used to analyze the association of occurrence of 
pDIs with specified risk factors, including gender, age, and the number 
of drugs prescribed. P<0.05 and P<0.01 were considered statistically 
significant and highly significant, respectively. All statistical analyses 
were done using the SPSS software database. Bar diagrams, tables, and 
charts were created using Microsoft Excel 2010 version to depict 
percentages and averages. 
RESULTS 
A total of 650 patients from eight different departments of the 
hospital were included in the study. Among them, 282 (43.38%) 
were males and 368 (56.61%) were females. The demographic 
profile of the patients is shown in table 1. The mean age of the study 
population was 39.67±15.23. The mean number of medications 
received per prescription in each dept is shown in fig. 1. 




Fig. 1: Mean no of medication per prescription in each department 
 
 
Fig. 2: Mean no of DIs per prescription in different departments of hospital 
 
 
Fig. 3: An outline of the whole study 
Jabeen et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 6, 59-67 
62 
A total of 487 pDDIs, 734 pDFIs, 586 pDAIs and 159 pDTIs were 
seen in 650 prescriptions from GM, OBG, Ortho, ENT, GS, Psych, 
Pulmo and Derm depts of a tertiary care teaching hospital. Fig. 3 
provided an outline of the whole study. 
The fig. 4 demonstrates the occurrence of pDDIs, pDFIs, pDAIs and 
pDTIs among different depts of hospital. The OBG and Pulmo dept 
has significantly higher DIs when compared to the other 6 depts. The 
Derm and ENT depts have the least number of DIs. 
 
 
Fig. 4: Comparison of DIs in different departments of hospital 
 
DDIs among different depts were the majority of moderate and 
minor types (fig. 5). 
Except psychiatry, moderate type of DFI were predominantly seen in 
all depts (fig. 6). 
 
 
Fig. 5: Severity of DDI in different departments of hospital 
 
 
Fig. 6: Severity of DFI in different departments of hospital 
 
The severity of DAI also followed a similar trend with moderate type 
predominating in all depts except medicine and surgery where 
major DAI are of a major type. Many contraindicated types of 
interactions have also been identified in various depts (fig. 7). 
 
 
Fig. 7: Severity of DAI in different departments of hospital 
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All the depts had the majority of major type of DTI (fig. 8). 
 
Fig. 8: Severity of DTI in different departments of hospital 
 
No significant difference among males and females with regard to 
severity of DIs were observed. 
The majority of DIs in different depts. of hospitals were PK in nature, 
except for the variations in dermatology and psychiatry (fig. 9). 
 
 
Fig. 9: Distribution of PK and PD interactions in different departments of hospital 
 
Logistic regression analysis showed a significant correlation with 
regard to the mean number of medications per prescription and 
mean no of potential DIs among different depts. of the hospital. 
(r=0.88. p=0.003488) fig. 10 
 
 
Fig. 10: Relationship between mean no of medications per prescription and mean no of DI per prescription 
 
There were no significant differences with regard to the age of 
patients and gender with number of DIs seen.  
Table 2,3,4, 5 shows the most common DI pairs in all the eight depts 
of the hospital. 
 
Table 2: Most common DDI pairs in all the eight departments of the hospital 






7, 4, 4 Minor,  
Moderate 
Moderate 
Increase concentrations of diclofenac, 
Increase blood levels of atorvastatin, 




35, 6, 2 Minor, Major 
Moderate 
Increase concentration of diclofenac 
Increased risk of bleeding, Increased blood 




40, 2, 2 Minor, 
Moderate Major 
Increase concentration of diclofenac, 




28, 4, 2 Minor Moderate 
Moderate 
Increase concentration of diclofenac, 
Increases risk of kidney damage Increase risk 
of bleeding  
Otolaryngology a.)Ceftriaxone+Diclofenac 
b.) Azithromycin+Moxifloxacin 





5, 4, 4 Moderate 
Moderate 
Moderate 
QT interval prolongation, Hypokalaemia and 





6, 6, 6  Moderate 
Moderate 
Moderate 
Decrease in olanzapine plasma concentration, 
Increase side effects like drowsiness, blurred 
vision, Increase side effects like drowsiness, 
blurred vision. 
Dermatology a.) Hydroxyzine+Cetirizine 1 Moderate Increase side effects like dizziness, 
drowsiness 
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Table 3: Most common DFI pairs in all the eight departments of the hospital 
Department Drug-food combination pairs No. of cases  Severity Consequences OF DFIs 







Moderate, Minor  
Moderate 
Reduced effectiveness of pantoprazole 
Decreased acetaminophen effectiveness. 







Decreased acetaminophen effectiveness. 
Reduced effectiveness of ranitidine. 






Reduced effectiveness of ranitidine. 










Reduced effectiveness of pantoprazole.  
Reduced effectiveness of ranitidine. 







Decreased effectiveness of ranitidine 










Decrease effectiveness of acetaminophen. 
Increased theophylline plasma levels. 
Altered theophylline concentration 






Decreased effect of chlordiazepoxide 
Decreased effects of clonazepam. 
Dermatology a.)Acetaminophen+Cabbage/Food 8 Moderate, Minor Decreased acetaminophen effectiveness. 
 
Table 4: Most common DAI pairs in all the eight departments of the hospital 







27, 15, 12 Major 
Moderate, C. I. 
Increased risk of hepatotoxicity, Increased 
bioavailability of alcohol, Disulfiram like 
reaction  
Orthopedic a.) Ranitidine+Alcohol  
b.) Acetaminophen+Alcohol 
57, 18 Moderate 
Major 
Increased bioavailability of alcohol, Increased 
risk of hepatotoxicity 
Gynecology a.) Metronidazole+Alcohol 
b.) Ranitidine+Alcohol 
50, 75 C. I, Moderate Disulfiram like reaction, Increased 
bioavailability of alcohol 
Surgery  a.) Ranitidine+Alcohol 
b.) Metronidazole+Alcohol  
c.) Tramadol+Alcohol 
22, 17, 16 Moderate, C. I. 
Major 
Increased bioavailability of alcohol, Disulfiram 
like reaction, Increased risk of respiratory 
depression 
Otolaryngology a.) Acetaminophen+Alcohol  
b.) Ranitidine+Alcohol 
10, 25  Major 
Moderate 
Increased risk of hepatotoxicity, Increased 
bioavailability of alcohol 
Pulmonology a.) Ranitidine+Alcohol  
b.) Acetaminophen+Alcohol 
6, 21 Moderate 
Major 
Increase bioavailability of alcohol. Increased 
risk of hepatotoxicity 
Psychiatry a.) Chlordiazepoxide+Alcohol  







Increased sedation  
Excessive C. N. S. depression, Increased 
sedation 
Dermatology a.) Levocetirizine+Alcohol 36 Moderate Increase nervous system side effects of 
levocetirizine  
 
Table 5: Most common DTI pairs in all the eight departments of the hospital 
Departments Drug-tobacco combination pairs No. of 
cases 
Severity Consequences of dtis 






Decreased exposure of CYP1A2 substrates 
Decreased exposure of CYP1A2 substrates 
Orthopaedic a.) Acetaminophen+Tobacco 18 Major Decreased exposure of CYP1A2 substrates  






Decreased exposure of CYP1A2 substrates 
Decreased exposure of CYP1A2 substrates  






Decreased exposure of CYP1A2 substrates 
Decreased exposure of CYP1A2 substrates 
Otolaryngology a.) Acetaminophen+Tobacco 10 Major Decreased exposure of CYP1A2 substrates  






Decreased exposure of CYP1A2 substrates 
Decreased exposure of CYP1A2 substrates 
Psychiatry a.) Olanzapine+Tobacco 8  Major Decreased exposure of CYP1A2 substrate 
Dermatology a.) Acetaminophen+Tobacco 21 Major Decreased exposure of CYP1A2 substrates  
 
DISCUSSION 
DIs, resulting in adverse drug events present a growing concern in 
healthcare settings. The patient requirement for multiple drug 
therapy, types of food intake, alcohol and tobacco habits, and the 
type of disease the patient is suffering from may result in decreased 
therapeutic benefit, adverse effect, or patient harm through a 
phenomenon called “Drug Interaction” [12].  
In our sample size of 650 patient’s medication profile, in which 
282(43.38%) were males and 368(56.61) were females. An increase 
in the female patient’s proportions could be due to n=100 female 
patients from the gynecology dept. The mean age of the study 
population was 39.67±15.23. There was no statistically significant 
difference among the mean age of patients in various depts and with 
respect to gender. Mean no of medication per prescription in 
different depts of the hospital are given in fig. 1, with the highest 
number obtained from OBG (5.5±1.38). These numbers were less 
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than the mean number of medications per prescriptions among 
geriatric patients (6.53±1.15) as reported by Varsha Shetty, et al. [2]. 
In our study, a total of 487 pDDIs were found in 650 patient 
medication profiles, with the highest number of pDDIs from OBG 
dept followed by Ortho, Pulmo, GS, Psych, GM, ENT and Derm having 
the least pDDIs. The highest number of pDDIs from OBG is in 
contrast from the study conducted by Lubinga SJ, et al. [13] which 
showed the less occurrence of pDDIs in OBG. As rightly stated by 
Ferracini A, et al. [14] during hospitalization, pregnant and 
breastfeeding women use a complex pharmacotherapy with many 
drugs prescribed, and hence their prescriptions are more 
susceptible to pDDIs. Pulmo, the second-highest contributor for 
pDDIs were having 48 pDDIs in 50 patients. A total of 29 patients 
(58%) in the Pulmo dept were having pDDIs pair contributing to a 
total of 48 pDDIs. A single prescription with 8 pDDIs and two 
prescriptions having 6 pDDIs each were identified. The higher 
occurrence of pDDIs in Ortho and GS is in accordance with the study 
conducted by Ramya Balaprabha G, et al. [15] with the use of 
antibiotics, analgesic and polypharmacy having contributed to these 
significantly higher numbers of pDDIs. In our study, the GM ward 
was having a moderately significant higher pDDIs. These could be 
due to variations in the study setting, number, and type of 
comorbidities as well as by the prescribing culture of the physician. 
However, the overall interaction rate was significantly higher in 
these depts. A total of 30 patients had contributed to 38 pDDIs in 
ENT. Lack of practical data was seen in the analysis of pDDIs in the 
ENT dept. As stated by Woroń J, et al. [16] concomitant use of drugs 
at the same time can lead to as high as 55% cases with DDIs in ENT 
dept. The least number of pDDIs in Derm dept were in accordance 
with the study conducted by Ramya Balaprabha G, et al. [15]. Pulmo 
(10%), Ortho (9%), and GS (5%) were having a higher number of 
major pDDIs. The majority of DDIs were moderate and minor in 
severity. The majority of interactions were PK in nature in 
accordance with the study conducted by Dais D, et al. [17]. 
Metabolism types of DDIs were predominant and were associated 
with the induction and inhibition of drug-metabolizing enzymes.  
We noticed that many of the drugs given during the hospital stay of 
the patient were repeated in the discharge summary chart, which 
the patient takes at home. Therefore, there is a high possibility of the 
patient taking medicine with certain food and beverages that may 
result in adverse consequences. 
It was observed that not much importance is given by the physician 
with regard to DFIs when writing a prescription. These interactions 
constitute a common hidden problem encountered in clinical practice. 
pDFIs either decrease the action of drugs or increase the action of 
drugs or cause adverse effects [9]. We, therefore, aim to evaluate the 
pDFIs occurring among different departments of hospitals. 
A total of 734 pDFIs were found in 650 patient’s medical records. 
The highest occurrence of DFIs was found in Pulmo dept with 88 
pDFIs were found in 50 patient’s medication chart, was in 
accordance with the study conducted by Ramalingam K et al. [16]. 
The GS, OBG, and Ortho had a significant higher number of pDFIs. 
Psych dept had moderately high pDFIs, with caffeine being the major 
reason for causing an additive pharmacodynamic interaction with 
psychiatric medications. The ENT and Derm had relatively less 
number of pDFIs.  
The majority of pDFIs were of moderate severity (73.16%). The 
study conducted by an Indian author among hospitalized cardiac 
patients also revealed a maximum number of DFIs were of moderate 
severity [18]. 92.64% of DFIs were PK in nature. Every intake of food 
may have a significant impact on the process of absorption, 
distribution, metabolism, and elimination relating to the higher 
occurring of PK DFIs [19]. 
The use of alcohol is common among both young and adults, males 
and females. Alcohol consumption in India amounted to about 5.4 
billion liters in 2016 and was estimated to reach about 6.5 billion 
liters by 2020 [20]. These numbers could be much higher for the 
rest of Asia and other countries globally. Despite this high 
prevalence, only a few physicians discuss alcohol use with their 
patients [21].  
In our study, a total of 586 pDAIs were found in a total of 650 
patient’s medical records. The highest number of pDAIs was found in 
OBG. This is of significant importance since alcohol consumption by 
pregnant women can have serious adverse effects on both the 
mother and the fetus. A survey conducted by CADD among 5,000 
Indian women aged between 17-80 y, revealed an increase in the 
rate of women drinking alcohol in India which could be due to peer 
pressure, exposure to a different lifestyle, and increased stress [22]. 
Therefore, the utmost caution should be given by the physician and 
pharmacist to the pregnant mother about alcohol-drug interactions 
that can have potential adverse life-threatening outcomes. The 
psychiatry department has the 2nd highest pDAIs with 46 (92%) of 
patients having at least 1 DAIs. As stated by Cheng C, et al. [23], 
individuals with mental health disorders are particularly vulnerable 
because of their psychotropic medications, which are typically taken 
for extended periods and are known to have PK and PD interactions 
with alcohol. The least number of pDAIs were found in the ENT dept. 
A major point to be noted is 34.01%, 22.97%, 16%, 5.45%, and 
3.37% patients in OBG, GS, GM, ENT, and Ortho respectively had 
pDAIs which are contraindicated. The majority of pDAIs were PK 
type (70.81%), this could be explained by the metabolism of alcohol 
by the alcohol-dehydrogenase enzyme in the liver and CYP450 
enzyme’s mainly CYP2E1 [21]. Psych and Derm had a higher number 
of PD type of pDAIs involving an increased risk of ADE or an 
increased susceptibility to the medication effects. 
Cigarette smoking remains highly prevalent in most of the countries. 
There are approximately 120 million smokers in India. According to 
WHO, India is home to 12% of the world’s smoker’s population [24]. 
Cigarette smoking induces several cytochrome enzyme’s preferably 
CYP450 enzymes, notably, CYP1A2. Medications metabolized by 
CYP1A2 will have a shorter duration of action [25]. 
A total of 159 pDTIs were seen in a total 650 patient’s medical 
profiles. An interesting finding is a total of only 10 pDTIs pair were 
seen in 650 patient’s which had contributed to a total of 159 pDTIs. 
98.44% of pDTIs were of PK in nature. 95.59% were found to be 
Major in severity. This impact of cigarette smoking needs to be 
considered in planning and assessing response to drug therapy. 
These interactions are difficult to observe clinically in patients 
because of shorter hospital stays of patients, incomplete information 
given by the patient to the doctor or pharmacist and the complexity 
of PK parameters to assess.  
Clinically relevant measures that can be taken to possibly avoid 
drug interactions 
• Concurrent use of Ceftriaxone and Diclofenac in prescriptions by 
the physician in many departments was seen. Although the 
interaction is minor and clinically not observed much, the 
interaction has exaggerated hemodynamically mediated Acute Renal 
Failure in a post-surgical patient [26]. Therefore, the patient’s on 
this combination therapy should be monitored for renal functions-
particularly volume-depleted patients, and can be avoided by 
removing or replacing NSAID with another analgesic or renal 
sparing NSAIDS (non-selective or coxib’s) can be preferred. 
• The interaction between Atorvastatin and Pantoprazole can be 
prevented by replacing Pantoprazole with other PPI like 
Rabeprazole [27].  
• The interaction between Clopidogrel and Pantoprazole can be 
prevented by replacing Pantoprazole with Ranitidine [27].  
• Concurrent use of two NSAIDs at the same time 
(Diclofenac+Aceclofenac) may increase the risk of side effects 
reported with this class of drug i.e. stomach ulcer, GI bleeding. This 
interaction can be prevented by combining NSAID with 
Acetaminophen for mild to moderate pain [28].  
• As Methotrexate and Prednisone is an effective combination for 
Rheumatoid Arthritis, the increased blood levels of Methotrexate 
and the adverse effect of this interaction can be prevented by giving 
low doses of Prednisone [29].  
• Concurrent use of Amikacin and Ceftriaxone may result in 
nephrotoxicity. The patient’s renal condition should be monitored 
particularly in volume-depleted patients and can be avoided by 
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replacing Ceftriaxone with an antibiotic that is not dependent on 
renal clearance or by reducing the dose of Ceftriaxone [30].  
• Concurrent use of Aspirin and Clopidogrel may cause unusual 
bleeding. The monitoring of blood count should be done if co-
administration is needed [31]. 
• Using Moxifloxacin with Azithromycin can increase the risk of an 
irregular heart rhythm that can be serious and life-threatening. The 
combination should be avoided and if suspected, immediate ECG 
monitoring and patient electrolyte condition or patient’s previous 
cardiovascular conditions should be evaluated [32].  
• Patients should be advised regarding cabbage and food intake 
with Acetaminophen [33].  
• Caffeine consumption altering the therapeutic response of 
Psychiatric medication and Theophylline can be prevented by 
advising the patient to avoid the use of caffeine and caffeinated 
products when prescription with such drugs are written [34]. 
• Often, DFIs can be avoided by prescribing the drug an hour 
before or after meal consumption. 
• Education of the patient on the potential risk factors associated 
with concurrent alcohol, tobacco, and medication use should be 
done by the Doctor and Clinical Pharmacist. 
However, as the development of clinically relevant DIs is reported to 
be unpredictable and may vary with an individual to individual, we 
agree with Janchawee B, et al. that DIs often need not always have 
clinically important adverse consequences but it is important to 
identify the DIs in order to prevent any harm to the patient's [35].  
Relating to the high prevalence of pDDIs, pDFIs, pDAIs, and pDTIs 
among different depts of the hospital, we recommend that Clinical 
Pharmacists should be posted in every hospital within India. 
Furthermore, a Clinical Pharmacist should have the skills and 
abilities to assess drug therapy, identify and prevent the medications 
that are having the potential to cause DIs, thereby minimizing the 
undesirable or adverse outcome in medical care and improving the 
quality of care given to the patients. 
The prescription should be essentially monitored in the respective 
dept's of the hospital found with which high prevalence rate of DIs. 
The food-related choice should be advised by the Clinical Pharmacist 
to the patient at the time of prescription review. 
As the teaching hospitals are the role models for the medical 
students, the prescribing behavior of the teacher can affect the 
students and can also influence the policymakers by informing them 
about the quality of drug use in health facilities.  
India, being the hub for the majority of the smoker’s globally, we, 
therefore, recommend the studies to be conducted with regard to 
the prevalence of alcohol and tobacco consumption among patient 
receiving medication, thereby preventing the DIs in this area and 
through education to the patient by the Clinical Pharmacist, 
Physician, and Health care professionals to promote safe and 
effective therapies.  
The pDIs observed in our study warrants the careful use of 
medications and their strict monitoring to avoid DIs. 
LIMITATIONS 
Our study is a medical record-based study and focuses on potential 
or theoretical DIs without direct interactions with the patient. The 
non-prescription drugs were not taken into account. Studies based 
on the prevalence of actual DIs among patients may be more 
significant providing real-time data. 
CONCLUSION  
In a country like India where the role of Clinical Pharmacist in the 
hospitalized setting is controversial, the large fig. of pDDIs, pDFIs, 
pDAIs, and pDTIs indicates their essential role in optimization of 
therapeutic regimen and quality of care provided to the patients. A 
characteristic pattern of DIs combination pairs were observed 
among the eight departments of the hospital. Hence these 
combinations should be corrected. Patient education regarding 
certain food choices, alcohol, and tobacco usage with medication 
should be given by the clinical pharmacist at the time of prescription 
review. The use of electronic systems for assessing DIs should be 
encouraged. A list of commonly used drug combination pairs found 
in the particular dept of the hospital can be given to the physician 
which helps in avoiding these DIs to the maximum and improves the 
quality of care provided to the patient. 
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